Dr. Sagar Salave is a multidisciplinary researcher specializing in nanotechnology, pharmaceutical biotechnology, vaccine development, and advanced drug delivery systems. He earned his Ph.D. from National Institute of Pharmaceutical Education and Research Ahmedabad (NIPER Ahmedabad), where his research focused on nanomedicine, pharmaceutical technologies, and therapeutic delivery systems. He is currently pursuing postdoctoral research at University of Kansas, working on mRNA vaccines and live viral vaccine platforms, including lipid nanoparticle-based delivery systems for next-generation therapeutics.
Dr. Salave has authored nearly 70 scientific publications in reputed international journals covering nanovaccines, nano-enabled drug delivery, infectious disease therapeutics, lipid nanoparticles, and advanced pharmaceutical formulations. His research integrates nanotechnology, immunology, molecular biology, and pharmaceutical engineering to develop innovative biomedical solutions.
He also gained industrial research experience at Lupin Limited, contributing to pharmaceutical formulation and translational biotechnology research. In addition to his research activities, he serves as a reviewer for nearly 50 international journals in biotechnology, nanomedicine, pharmaceutical sciences, and biomedical engineering. He is associated with Applied Biochemistry and Biotechnology as an editor and serves on the editorial boards of several international journals, reflecting his active cont
Dr. Sagar Salave is a multidisciplinary researcher specializing in nanotechnology, pharmaceutical biotechnology, vaccine development, and advanced drug delivery systems. He earned his Ph.D. from National Institute of Pharmaceutical Education and Research Ahmedabad (NIPER Ahmedabad), where his research focused on nanomedicine, pharmaceutical technologies, and therapeutic delivery systems. He is currently pursuing postdoctoral research at University of Kansas, working on mRNA vaccines and live viral vaccine platforms, including lipid nanoparticle-based delivery systems for next-generation therapeutics.
Dr. Salave has authored nearly 70 scientific publications in reputed international journals covering nanovaccines, nano-enabled drug delivery, infectious disease therapeutics, lipid nanoparticles, and advanced pharmaceutical formulations. His research integrates nanotechnology, immunology, molecular biology, and pharmaceutical engineering to develop innovative biomedical solutions.
He also gained industrial research experience at Lupin Limited, contributing to pharmaceutical formulation and translational biotechnology research. In addition to his research activities, he serves as a reviewer for nearly 50 international journals in biotechnology, nanomedicine, pharmaceutical sciences, and biomedical engineering. He is associated with Applied Biochemistry and Biotechnology as an editor and serves on the editorial boards of several international journals, reflecting his active cont